...Chemical Co. Ltd. , Eisai Co. Ltd. and Taisho Pharmaceutical Holdings Co. Ltd. market Careram iguratimod...

...Eisai and Toyama said Japan lifted the condition for approval of Careram/Kolbet iguratimod to treat rheumatoid...
...and Toyama, independently market the product in the country under the brand names Careram and Kolbet...
...Japan Toyama Chemical Co. Ltd. , Tokyo, Japan Product: Careram ( Kolbet ) iguratimod ( T-614...

...Simcere disclosed in its 4Q11 earnings that during 1Q12 it launched Iremod iguratimod to treat rheumatoid...

...vedotin Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL) U.S. Simcere Pharmaceutical Group (NYSE:SCR) Iremod iguratimod...

...icatibant for acute attacks of hereditary angioedema (HAE) Simcere Pharmaceutical Group (NYSE:SCR) China approves Iremod iguratimod...

...Eisai submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for iguratimod...
...Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Toyama Chemical Co. Ltd. (Tokyo:4518), Tokyo, Japan Product: Iguratimod ( T-614...

...partner Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) submitted a regulatory application in Japan for iguratimod ( T-614...

...$0.08 to $8.60 last week after China's State Food and Drug Administration (SFDA) approved Iremod iguratimod...

...Simcere said China's State Food and Drug Administration approved Iremod iguratimod to treat rheumatoid arthritis (RA...
...Simcere said the compound is a DMARD. Simcere Pharmaceutical Group (NYSE:SCR), Nanjing, China Product: Iremod iguratimod...

...Simcere Pharmaceutical Group (NYSE:SCR) said China's State Food and Drug Administration approved Iremod iguratimod to treat...